Table of Contents
ISRN Anesthesiology
Volume 2011 (2011), Article ID 593894, 19 pages
http://dx.doi.org/10.5402/2011/593894
Review Article

The Central Role of Glia in Pathological Pain and the Potential of Targeting the Cannabinoid 2 Receptor for Pain Relief

Department of Neurosciences, School of Medicine, University of New Mexico, HSC, MSC08-4740, Albuquerque, NM 87131, USA

Received 17 August 2011; Accepted 17 September 2011

Academic Editor: J. H. Abraini

Copyright © 2011 Jenny L. Wilkerson and Erin D. Milligan. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Centers for Disease Control and Prevention, Health, United States, With Special Feature on Pain, Centers for Disease Control and Prevention's (CDC) National Center for Health Statistics, 2006.
  2. C. E. Argoff, B. E. Cole, D. A. Fishbain, and G. A. Irving, “Diabetic peripheral neuropathic pain: clinical and quality-of-life issues,” Mayo Clinic Proceedings, vol. 81, no. 4, supplement, pp. S3–S11, 2006. View at Google Scholar · View at Scopus
  3. P. J. Christo and D. Mazloomdoost, “Cancer pain and analgesia,” Annals of the New York Academy of Sciences, vol. 1138, pp. 278–298, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. C. Douglas, J. A. Wollin, and C. Windsor, “Illness and demographic correlates of chronic pain among a community-based sample of people with multiple sclerosis,” Archives of Physical Medicine and Rehabilitation, vol. 89, no. 10, pp. 1923–1932, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. A. S. Russell, “Quality-of-life assessment in rheumatoid arthritis,” Pharmacoeconomics, vol. 26, no. 10, pp. 831–846, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. Winter, K. Schepelmann, A. E. Spottke et al., “Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy,” Journal of Neurology, vol. 257, no. 9, pp. 1473–1481, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. J. Guindon and A. G. Hohmann, “Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain,” British Journal of Pharmacology, vol. 153, no. 2, pp. 319–334, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. N. Stella, “Endocannabinoid signaling in microglial cells,” Neuropharmacology, vol. 56, supplement 1, pp. 244–253, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. A. D. Craig, “Distribution of brainstem projections from spinal lamina I neurons in the cat and the monkey,” Journal of Comparative Neurology, vol. 361, no. 2, pp. 225–248, 1995. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. L. Villanueva and J. F. Bernard, “The multiplicity of ascending pain pathways,” in Handbook of Behavioral State Control: Cellular and Molecular Mechanisms, R. Lydic and H. A. Baghdoyan, Eds., pp. 569–585, CRC Press, Boca Raton, Fla, USA, 1999. View at Google Scholar
  11. W. D. Willis and R. E. Coggeshall, Sensory Mechanisms of the Spinal Cord, Plenum Press, New York, NY, USA, 2nd edition, 1991.
  12. A. Berthele, S. J. Boxall, A. Urban et al., “Distribution and developmental changes in metabotropic glutamate receptor messenger RNA expression in the rat lumbar spinal cord,” Developmental Brain Research, vol. 112, no. 1, pp. 39–53, 1999. View at Publisher · View at Google Scholar · View at Scopus
  13. S. N. Lawson, B. A. Crepps, and E. R. Perl, “Relationship of substance P to afferent characteristics of dorsal root ganglion neurones in guinea-pig,” Journal of Physiology, vol. 505, part 1, pp. 177–191, 1997. View at Google Scholar · View at Scopus
  14. S. P. Hunt and P. W. Mantyh, “The molecular dynamics of pain control,” Nature Reviews Neuroscience, vol. 2, no. 2, pp. 83–91, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. M. Costigan, J. Scholz, and C. J. Woolf, “Neuropathic pain: a maladaptive response of the nervous system to damage,” Annual Review of Neuroscience, vol. 32, pp. 1–32, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. C. J. Woolf and M. W. Salter, “Neuronal plasticity: increasing the gain in pain,” Science, vol. 288, no. 5472, pp. 1765–1768, 2000. View at Google Scholar · View at Scopus
  17. A. J. Cook, C. J. Woolf, P. D. Wall, and S. B. McMahon, “Dynamic receptive field plasticity in rat spinal cord dorsal horn following C-primary afferent input,” Nature, vol. 325, no. 7000, pp. 151–153, 1987. View at Google Scholar · View at Scopus
  18. P. D. Wall and C. J. Woolf, “The brief and the prolonged facilitatory effects of unmyelinated afferent input on the rat spinal cord are independently influenced by peripheral nerve section,” Neuroscience, vol. 17, no. 4, pp. 1199–1205, 1986. View at Google Scholar · View at Scopus
  19. K. M. Baumbauer, E. E. Young, and R. L. Joynes, “Pain and learning in a spinal system: contradictory outcomes from common origins,” Brain Research Reviews, vol. 61, no. 2, pp. 124–143, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. C. Luo, P. H. Seeburg, R. Sprengel, and R. Kuner, “Activity-dependent potentiation of calcium signals in spinal sensory networks in inflammatory pain states,” Pain, vol. 140, no. 2, pp. 358–367, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. M. H. Ossipov, J. Lai, T. P. Malan, and F. Porreca, “Spinal and supraspinal mechanisms of neuropathic pain,” Annals of the New York Academy of Sciences, vol. 909, pp. 12–24, 2000. View at Google Scholar · View at Scopus
  22. R. R. Ji and C. J. Woolf, “Neuronal plasticity and signal transduction in nociceptive neurons: implications for the initiation and maintenance of pathological pain,” Neurobiology of Disease, vol. 8, no. 1, pp. 1–10, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. D. A. Simone, T. K. Baumann, J. G. Collins, and R. H. LaMotte, “Sensitization of cat dorsal horn neurons to innocuous mechanical stimulation after intradermal injection of capsaicin,” Brain Research, vol. 486, no. 1, pp. 185–189, 1989. View at Google Scholar · View at Scopus
  24. J. A. DeLeo, L. S. Sorkin, and L. R. Watkins, Eds., Immune and Glial Regulation of Pain, IASP Press, Seattle, Wash, USA, 2007.
  25. J. A. De Leo, V. L. Tawfik, and M. L. LaCroix-Fralish, “The tetrapartite synapse: path to CNS sensitization and chronic pain,” Pain, vol. 122, no. 1-2, pp. 17–21, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. H. Hashizume, J. A. DeLeo, R. W. Colburn, and J. N. Weinstein, “Spinal glial activation and cytokine expression after lumbar root injury in the rat,” Spine, vol. 25, no. 10, pp. 1206–1217, 2000. View at Publisher · View at Google Scholar · View at Scopus
  27. R. R. Ji, R. W. Gereau IV, M. Malcangio, and G. R. Strichartz, “MAP kinase and pain,” Brain Research Reviews, vol. 60, no. 1, pp. 135–148, 2009. View at Publisher · View at Google Scholar · View at PubMed
  28. A. Ledeboer, M. Gamanos, W. Lai et al., “Involvement of spinal cord nuclear factor κB activation in rat models of proinflammatory cytokine-mediated pain facilitation,” European Journal of Neuroscience, vol. 22, no. 8, pp. 1977–1986, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. E. D. Milligan and L. R. Watkins, “Pathological and protective roles of glia in chronic pain,” Nature Reviews Neuroscience, vol. 10, no. 1, pp. 23–36, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. L. R. Watkins, M. R. Hutchinson, A. Ledeboer et al., “Norman cousins lecture. Glia as the “bad guys”: implications for improving clinical pain control and the clinical utility of opioids,” Brain, Behavior, and Immunity, vol. 21, no. 2, pp. 131–146, 2007. View at Google Scholar
  31. R. R. Ji and G. Strichartz, “Cell signaling and the genesis of neuropathic pain,” Science's Stke, vol. 2004, no. 252, p. reE14, 2004. View at Google Scholar · View at Scopus
  32. J. P. White, M. Cibelli, A. R. Fidalgo, and I. Nagy, “Extracellular signal-regulated kinases in pain of peripheral origin,” European Journal of Pharmacology, vol. 650, no. 1, pp. 8–17, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. Y. J. Gao, L. Zhang, O. A. Samad et al., “JNK-induced MCP-1 production in spinal cord astrocytes contributes to central sensitization and neuropathic pain,” Journal of Neuroscience, vol. 29, no. 13, pp. 4096–4108, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. S. X. Jin, Z. Y. Zhuang, C. J. Woolf, and R. R. Ji, “p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain,” Journal of Neuroscience, vol. 23, no. 10, pp. 4017–4022, 2003. View at Google Scholar · View at Scopus
  35. H. Katsura, K. Obata, T. Mizushima et al., “Activation of Src-family kinases in spinal microglia contributes to mechanical hypersensitivity after nerve injury,” Journal of Neuroscience, vol. 26, no. 34, pp. 8680–8690, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. Y. R. Wen, M. R. Suter, R. R. Ji et al., “Activation of p38 mitogen-activated protein kinase in spinal microglia contributes to incision-induced mechanical allodynia,” Anesthesiology, vol. 110, no. 1, pp. 155–165, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. Z. Y. Zhuang, Y. R. Wen, D. R. Zhang et al., “A peptide c-Jun N-terminal kinase (JNK) inhibitor blocks mechanical allodynia after spinal nerve ligation: respective roles of JNK activation in primary sensory neurons and spinal astrocytes for neuropathic pain development and maintenance,” Journal of Neuroscience, vol. 26, no. 13, pp. 3551–3560, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. J. I. Choi, C. I. Svensson, F. J. Koehrn, A. Bhuskute, and L. S. Sorkin, “Peripheral inflammation induces tumor necrosis factor dependent AMPA receptor trafficking and Akt phosphorylation in spinal cord in addition to pain behavior,” Pain, vol. 149, no. 2, pp. 243–253, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. F. A. White, S. K. Bhangoo, and R. J. Miller, “Chemokines: integrators of pain and inflammation,” Nature Reviews Drug Discovery, vol. 4, no. 10, pp. 834–844, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. C. L. Willis and T. P. Davis, “Chronic inflammatory pain and the neurovascular unit: a central role for glia in maintaining BBB integrity?” Current Pharmaceutical Design, vol. 14, no. 16, pp. 1625–1643, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. N. R. Bhat, P. Zhang, J. C. Lee, and E. L. Hogan, “Extracellular signal-regulated kinase and p38 subgroups of mitogen- activated protein kinases regulate inducible nitric oxide synthase and tumor necrosis factor-α gene expression in endotoxin-stimulated primary glial cultures,” Journal of Neuroscience, vol. 18, no. 5, pp. 1633–1641, 1998. View at Google Scholar · View at Scopus
  42. D. Levy, A. Hoke, and D. W. Zochodne, “Local expression of inducible nitric oxide synthase in an animal model of neuropathic pain,” Neuroscience Letters, vol. 260, no. 3, pp. 207–209, 1999. View at Publisher · View at Google Scholar · View at Scopus
  43. D. Levy and D. W. Zochodne, “NO pain: potential roles of nitric oxide in neuropathic pain,” Pain Practice, vol. 4, no. 1, pp. 11–18, 2004. View at Google Scholar
  44. S. T. Meller and G. F. Gebhart, “Nitric oxide (NO) and nociceptive processing in the spinal cord,” Pain, vol. 52, no. 2, pp. 127–136, 1993. View at Publisher · View at Google Scholar · View at Scopus
  45. J. M. Cavaillon and D. Annane, “Compartmentalization of the inflammatory response in sepsis and SIRS,” Journal of Endotoxin Research, vol. 12, no. 3, pp. 151–170, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. T. Kato and S. Kitagawa, “Regulation of neutrophil functions by proinflammatory cytokines,” International Journal of Hematology, vol. 84, no. 3, pp. 205–209, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. B. León and C. Ardavín, “Monocyte-derived dendritic cells in innate and adaptive immunity,” Immunology and Cell Biology, vol. 86, no. 4, pp. 320–324, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. R. E. Simmonds and B. M. Foxwell, “Signalling, inflammation and arthritis: NF-κB and its relevance to arthritis and inflammation,” Rheumatology, vol. 47, no. 5, pp. 584–590, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. F. A. White, J. Sun, S. M. Waters et al., “Excitatory monocyte chemoattractant protein-1 signaling is up-regulated in sensory neurons after chronic compression of the dorsal root ganglion,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 39, pp. 14092–14097, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. M. Pekny and M. Pekna, “Astrocyte intermediate filaments in CNS pathologies and regeneration,” Journal of Pathology, vol. 204, no. 4, pp. 428–437, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. L. F. Eng, R. S. Ghirnikar, and Y. L. Lee, “Glial fibrillary acidic protein: GFAP-thirty-one years (1969–2000),” Neurochemical Research, vol. 25, no. 9-10, pp. 1439–1451, 2000. View at Google Scholar · View at Scopus
  52. S. Echeverry, X. Q. Shi, and J. Zhang, “Characterization of cell proliferation in rat spinal cord following peripheral nerve injury and the relationship with neuropathic pain,” Pain, vol. 135, no. 1-2, pp. 37–47, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. Y. Imai, I. Ibata, D. Ito, K. Ohsawa, and S. Kohsaka, “A novel gene iba1 in the major histocompatibility complex class III region encoding an EF hand protein expressed in a monocytic lineage,” Biochemical and Biophysical Research Communications, vol. 224, no. 3, pp. 855–862, 1996. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. S. M. McKay, D. J. Brooks, P. Hu, and E. M. McLachlan, “Distinct types of microglial activation in white and grey matter of rat lumbosacral cord after mid-thoracic spinal transection,” Journal of Neuropathology and Experimental Neurology, vol. 66, no. 8, pp. 698–710, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. J. Mika, M. Osikowicz, E. Rojewska et al., “Differential activation of spinal microglial and astroglial cells in a mouse model of peripheral neuropathic pain,” European Journal of Pharmacology, vol. 623, no. 1–3, pp. 65–72, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. I. Mori, Y. Imai, S. Kohsaka, and Y. Kimura, “Upregulated expression of Iba1 molecules in the central nervous system of mice in response to neurovirulent influenza A virus infection,” Microbiology and Immunology, vol. 44, no. 8, pp. 729–735, 2000. View at Google Scholar · View at Scopus
  57. K. Ohsawa, Y. Imai, H. Kanazawa, Y. Sasaki, and S. Kohsaka, “Involvement of Iba1 in membrane ruffling and phagocytosis of macrophages/microglia,” Journal of Cell Science, vol. 113, part 17, pp. 3073–3084, 2000. View at Google Scholar · View at Scopus
  58. S. K. Moestrup and H. J. Moller, “CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response,” Annals of Medicine, vol. 36, no. 5, pp. 347–354, 2004. View at Publisher · View at Google Scholar · View at Scopus
  59. F. Porcheray, S. Viaud, A. C. Rimaniol et al., “Macrophage activation switching: an asset for the resolution of inflammation,” Clinical and Experimental Immunology, vol. 142, no. 3, pp. 481–489, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  60. Y. Yiangou, P. Facer, P. Durrenberger et al., “COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord,” BMC Neurology, vol. 6, article 12, 2006. View at Publisher · View at Google Scholar · View at PubMed
  61. W. R. Yu, T. Liu, T. -R. Kiehl, and M. G. Fehlings, “Human neuropathological and animal model evidence supporting a role for Fas-mediated apoptosis and inflammation in cervical spondylotic myelopathy,” Brain, vol. 134, part 5, pp. 1277–1292, 2011. View at Publisher · View at Google Scholar · View at PubMed
  62. R. J. Horvath, R. P. Landry, E. A. Romero-Sandoval, and J. A. DeLeo, “Morphine tolerance attenuates the resolution of postoperative pain and enhances spinal microglial p38 and extracellular receptor kinase phosphorylation,” Neuroscience, vol. 169, no. 2, pp. 843–854, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. M. S. Alkaitis, C. Solorzano, R. P. Landry, D. Piomelli, J. A. DeLeo, and E. A. Romero-Sandoval, “Evidence for a role of endocannabinoids, astrocytes and p38 phosphorylation in the resolution of postoperative pain,” Plos One, vol. 5, no. 5, p. e10891, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  64. E. D. Ponomarev, K. Maresz, Y. Tan, and B. N. Dittel, “CNS-derived interleukin-4 is essential for the regulation of autoimmune inflammation and induces a state of alternative activation in microglial cells,” Journal of Neuroscience, vol. 27, no. 40, pp. 10714–10721, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  65. Z. Wu, J. Zhang, and H. Nakanishi, “Leptomeningeal cells activate microglia and astrocytes to induce IL-10 production by releasing pro-inflammatory cytokines during systemic inflammation,” Journal of Neuroimmunology, vol. 167, no. 1-2, pp. 90–98, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  66. S. Kunori, S. Matsumura, E. Okuda-Ashitaka et al., “A novel role of prostaglandin E2 in neuropathic pain: blockade of microglial migration in the spinal cord,” GLIA, vol. 59, no. 2, pp. 208–218, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  67. J. Wieseler-Frank, B. M. Jekich, J. H. Mahoney, S. T. Bland, S. F. Maier, and L. R. Watkins, “A novel immune-to-CNS communication pathway: cells of the meninges surrounding the spinal cord CSF space produce proinflammatory cytokines in response to an inflammatory stimulus,” Brain, Behavior, and Immunity, vol. 21, no. 5, pp. 711–718, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  68. T. Rice, J. Larsen, S. Rivest, and V. W. Yong, “Characterization of the early neuroinflammation after spinal cord injury in mice,” Journal of Neuropathology and Experimental Neurology, vol. 66, no. 3, pp. 184–195, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  69. M. Takeda, M. Takahashi, and S. Matsumoto, “Contribution of the activation of satellite glia in sensory ganglia to pathological pain,” Neuroscience and Biobehavioral Reviews, vol. 33, no. 6, pp. 784–792, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  70. M. Hanani, “Satellite glial cells in sensory ganglia: from form to function,” Brain Research Reviews, vol. 48, no. 3, pp. 457–476, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  71. K. Otoshi, S. I. Kikuchi, S. I. Konno, and M. Sekiguchi, “The reactions of glial cells and endoneurial macrophages in the dorsal root ganglion and their contribution to pain-related behavior after application of nucleus pulposus onto the nerve root in rats,” Spine, vol. 35, no. 3, pp. 264–271, 2010. View at Google Scholar · View at Scopus
  72. K. Siemionow, A. Klimczak, G. Brzezicki, M. Siemionow, and R. F. McLain, “The effects of inflammation on glial fibrillary acidic protein expression in satellite cells of the dorsal root ganglion,” Spine, vol. 34, no. 16, pp. 1631–1637, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  73. M. Takeda, M. Takahashi, and S. Matsumoto, “Contribution of activated interleukin receptors in trigeminal ganglion neurons to hyperalgesia via satellite glial interleukin-1β paracrine mechanism,” Brain, Behavior, and Immunity, vol. 22, no. 7, pp. 1016–1023, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  74. R. Jancalek, P. Dubovy, I. Svizenska, and I. Klusakova, “Bilateral changes of TNF-α and IL-10 protein in the lumbar and cervical dorsal root ganglia following a unilateral chronic constriction injury of the sciatic nerve,” Journal of Neuroinflammation, vol. 7, article 11, 2010. View at Publisher · View at Google Scholar · View at PubMed
  75. A. M. Skoff, C. Zhao, and J. E. Adler, “Interleukin-1α regulates substance P expression and release in adult sensory neurons,” Experimental Neurology, vol. 217, no. 2, pp. 395–400, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  76. P. Dubovy, L. Tuackova, R. Janaclek, I. Svizenska, and I. Klusakova, “Increased invasion of ED-1 positive macrophages in both ipsi- and contralateral dorsal root ganglia following unilateral nerve injuries,” Neuroscience Letters, vol. 427, no. 2, pp. 88–93, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  77. P. Hu, A. L. Bembrick, K. A. Keay, and E. M. McLachlan, “Immune cell involvement in dorsal root ganglia and spinal cord after chronic constriction or transection of the rat sciatic nerve,” Brain, Behavior, and Immunity, vol. 21, no. 5, pp. 599–616, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  78. P. Hu and E. M. McLachlan, “Macrophage and lymphocyte invasion of dorsal root ganglia after peripheral nerve lesions in the rat,” Neuroscience, vol. 112, no. 1, pp. 23–38, 2002. View at Publisher · View at Google Scholar · View at Scopus
  79. N. Morin, S. A. Owolabi, M. W. Harty et al., “Neutrophils invade lumbar dorsal root ganglia after chronic constriction injury of the sciatic nerve,” Journal of Neuroimmunology, vol. 184, no. 1-2, pp. 164–171, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  80. S. Bhangoo, D. Ren, R. J. Miller et al., “Delayed functional expression of neuronal chemokine receptors following focal nerve demyelination in the rat: a mechanism for the development of chronic sensitization of peripheral nociceptors,” Molecular Pain, vol. 3, article 38, 2007. View at Publisher · View at Google Scholar · View at PubMed
  81. H. Jung, P. T. Toth, F. A. White, and R. J. Miller, “Monocyte chemoattractant protein-1 functions as a neuromodulator in dorsal root ganglia neurons,” Journal of Neurochemistry, vol. 104, no. 1, pp. 254–263, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  82. A. M. Binshtok, H. Wang, K. Zimmermann et al., “Nociceptors are interleukin-1β sensors,” Journal of Neuroscience, vol. 28, no. 52, pp. 14062–14073, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  83. J. C. V. M. Copray, I. Mantingh, N. Brouwer et al., “Expression of interleukin-1 β in rat dorsal root ganglia,” Journal of Neuroimmunology, vol. 118, no. 2, pp. 203–211, 2001. View at Publisher · View at Google Scholar · View at Scopus
  84. O. Obreja, P. K. Rathee, K. S. Lips, C. Distler, and M. Kress, “IL-1β potentiates heat-activated currents in rat sensory neurons: involvement of IL-1RI, tyrosine kinase, and protein kinase C,” Faseb Journal, vol. 16, no. 12, pp. 1497–1503, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  85. A. Inoue, K. Ikoma, N. Morioka et al., “Interleukin-1β induces substance P release from primary afferent neurons through the cyclooxygenase-2 system,” Journal of Neurochemistry, vol. 73, no. 5, pp. 2206–2213, 1999. View at Google Scholar · View at Scopus
  86. R. R. Ji, T. A. Samad, S. X. Jin, R. Schmoll, and C. J. Woolf, “p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia,” Neuron, vol. 36, no. 1, pp. 57–68, 2002. View at Publisher · View at Google Scholar · View at Scopus
  87. J. T. Xu, W. J. Xin, X. H. Wei et al., “p38 activation in uninjured primary afferent neurons and in spinal microglia contributes to the development of neuropathic pain induced by selective motor fiber injury,” Experimental Neurology, vol. 204, no. 1, pp. 355–365, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  88. L. R. Watkins and S. F. Maier, “Targeting glia to control clinical pain: an idea whose time has come,” Drug Discovery Today: Therapeutic Strategies, vol. 1, no. 1, pp. 83–88, 2004. View at Publisher · View at Google Scholar · View at Scopus
  89. A. Ledeboer, E. M. Sloane, E. D. Milligan et al., “Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation,” Pain, vol. 115, no. 1-2, pp. 71–83, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  90. Y. W. Chang and S. G. Waxman, “Minocycline attenuates mechanical allodynia and central sensitization following peripheral second-degree burn injury,” Journal of Pain, vol. 11, no. 11, pp. 1146–1154, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  91. C. C. Liu, N. Lu, Y. Cui et al., “Prevention of paclitaxel-induced allodynia by minocycline: effect on loss of peripheral nerve fibers and infiltration of macrophages in rats,” Molecular Pain, vol. 6, article 76, 2010. View at Publisher · View at Google Scholar · View at PubMed
  92. F. Giuliani, W. Hader, and V. W. Yong, “Minocycline attenuates T cell and microglia activity to impair cytokine production in T cell-microglia interaction,” Journal of Leukocyte Biology, vol. 78, no. 1, pp. 135–143, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  93. E. A. Romero-Sandoval, R. Horvath, R. P. Landry, and J. A. DeLeo, “Cannabinoid receptor type 2 activation induces a microglial anti-inflammatory phenotype and reduces migration via MKP induction and ERK dephosphorylation,” Molecular Pain, vol. 5, article 25, 2009. View at Publisher · View at Google Scholar · View at PubMed
  94. L. Walter, A. Franklin, A. Witting et al., “Nonpsychotropic cannabinoid receptors regulate microglial cell migration,” Journal of Neuroscience, vol. 23, no. 4, pp. 1398–1405, 2003. View at Google Scholar · View at Scopus
  95. I. Racz, X. Nadal, J. Alferink et al., “Crucial role of CB2 cannabinoid receptor in the regulation of central immune responses during neuropathic pain,” Journal of Neuroscience, vol. 28, no. 46, pp. 12125–12135, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  96. A. Romero-Sandoval, N. Nutile-Mcmenemy, and J. A. Deleo, “Spinal microglial and perivascular cell cannabinoid receptor type 2 activation reduces behavioral hypersensitivity without tolerance after peripheral nerve injury,” Anesthesiology, vol. 108, no. 4, pp. 722–734, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  97. A. Calignano, G. La Rana, A. Giuffrida, and D. Piomelli, “Control of pain initiation by endogenous cannabinoids,” Nature, vol. 394, no. 6690, pp. 277–281, 1998. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  98. J. D. Richardson, L. Aanonsen, and K. M. Hargreaves, “Antihyperalgesic effects of spinal cannabinoids,” European Journal of Pharmacology, vol. 345, no. 2, pp. 145–153, 1998. View at Publisher · View at Google Scholar · View at Scopus
  99. J. D. Richardson, S. Kilo, and K. M. Hargreaves, “Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors,” Pain, vol. 75, no. 1, pp. 111–119, 1998. View at Publisher · View at Google Scholar · View at Scopus
  100. A. Moriconi, I. Cerbara, M. Maccarrone, and A. Topai, “GPR55: current knowledge and future perspectives of a purported “type-3” cannabinoid receptor,” Current Medicinal Chemistry, vol. 17, no. 14, pp. 1411–1429, 2010. View at Publisher · View at Google Scholar · View at Scopus
  101. D. G. Johns, D. J. Behm, D. J. Walker et al., “The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects,” British Journal of Pharmacology, vol. 152, no. 5, pp. 825–831, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  102. J. E. Lauckner, J. B. Jensen, H. Y. Chen, H. C. Lu, B. Hille, and K. Mackie, “GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 7, pp. 2699–2704, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  103. S. Oka, K. Nakajima, A. Yamashita, S. Kishimoto, and T. Sugiura, “Identification of GPR55 as a lysophosphatidylinositol receptor,” Biochemical and Biophysical Research Communications, vol. 362, no. 4, pp. 928–934, 2007. View at Publisher · View at Google Scholar · View at PubMed
  104. E. Ryberg, N. Larsson, S. Sjogren et al., “The orphan receptor GPR55 is a novel cannabinoid receptor,” British Journal of Pharmacology, vol. 152, no. 7, pp. 1092–1101, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  105. E. Kotsikorou, D. L. Lynch, M. E. Abood, and P. H. Reggio, “Lipid bilayer molecular dynamics study of lipid-derived agonists of the putative cannabinoid receptor, GPR55,” Chemistry and Physics of Lipids, vol. 164, no. 2, pp. 131–143, 2011. View at Publisher · View at Google Scholar · View at PubMed
  106. H. Sharir and M. E. Abood, “Pharmacological characterization of GPR55, a putative cannabinoid receptor,” Pharmacology and Therapeutics, vol. 126, no. 3, pp. 301–313, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  107. P. C. Staton, J. P. Hatcher, D. J. Walker et al., “The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain,” Pain, vol. 139, no. 1, pp. 225–236, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  108. A. C. Howlett, “Cannabinoid receptor signaling,” Handbook of Experimental Pharmacology, no. 168, pp. 53–79, 2005. View at Google Scholar
  109. S. Mitrirattanakul, N. Ramakul, A. V. Guerrero et al., “Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain,” Pain, vol. 126, no. 1–3, pp. 102–114, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  110. I. Svizenska, P. Dubovy, and A. Sulcova, “Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures—a short review,” Pharmacology Biochemistry and Behavior, vol. 90, no. 4, pp. 501–511, 2008. View at Publisher · View at Google Scholar · View at PubMed
  111. S. Munro, K. L. Thomas, and M. Abu-Shaar, “Molecular characterization of a peripheral receptor for cannabinoids,” Nature, vol. 365, no. 6441, pp. 61–65, 1993. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  112. M. Bouaboula, M. Rinaldi, P. Carayon et al., “Cannabinoid-receptor expression in human leukocytes,” European Journal of Biochemistry, vol. 214, no. 1, pp. 173–180, 1993. View at Google Scholar · View at Scopus
  113. S. Galiegue, S. Mary, J. Marchand et al., “Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations,” European Journal of Biochemistry, vol. 232, no. 1, pp. 54–61, 1995. View at Publisher · View at Google Scholar · View at Scopus
  114. M. Bouaboula, C. Poinot-Chazel, J. Marchand et al., “Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor: involvement of both mitogen-activated protein kinase and induction of Krox-24 expression,” European Journal of Biochemistry, vol. 237, no. 3, pp. 704–711, 1996. View at Google Scholar · View at Scopus
  115. D. M. Slipetz, G. P. O'Neill, L. Favreau et al., “Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase,” Molecular Pharmacology, vol. 48, no. 2, pp. 352–361, 1995. View at Google Scholar · View at Scopus
  116. M. Bidaut-Russell, W. A. Devane, and A. C. Howlett, “Cannabinoid receptors and modulation of cyclic AMP accumulation in the rat brain,” Journal of Neurochemistry, vol. 55, no. 1, pp. 21–26, 1990. View at Publisher · View at Google Scholar · View at Scopus
  117. A. C. Howlett, “Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes,” Molecular Pharmacology, vol. 27, no. 4, pp. 429–436, 1985. View at Google Scholar · View at Scopus
  118. K. Mackie and B. Hille, “Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 9, pp. 3825–3829, 1992. View at Google Scholar · View at Scopus
  119. J. Liu, B. Gao, F. Mirshahi et al., “Functional CB1 cannabinoid receptors in human vascular endothelial cells,” Biochemical Journal, vol. 346, no. 3, pp. 835–840, 2000. View at Publisher · View at Google Scholar · View at Scopus
  120. D. Rueda, I. Galve-Roperh, A. Haro, and M. Guzman, “The CB1 cannabinoid receptor is coupled to the activation of c-jun N-terminal kinase,” Molecular Pharmacology, vol. 58, no. 4, pp. 814–820, 2000. View at Google Scholar · View at Scopus
  121. T. Y. Jen, G. A. Hughes, and H. Smith, “Total synthesis of Δ8-(Δ1(6))-tetrahydrocannabinol, a biologically active constituent of hashish (marijuana),” Journal of the American Chemical Society, vol. 89, no. 17, pp. 4551–4552, 1967. View at Google Scholar · View at Scopus
  122. R. Mechoulam and Y. Gaoni, “A total synthesis of dl-Δ1-tetrahydrocannabinol, the active constituent of hashish,” Journal of the American Chemical Society, vol. 87, no. 14, pp. 3273–3275, 1965. View at Google Scholar · View at Scopus
  123. R. Mechoulam and Y. Gaoni, “Hashish-IV. The isolation and structure of cannabinolic cannabidiolic and cannabigerolic acids,” Tetrahedron, vol. 21, no. 5, pp. 1223–1229, 1965. View at Google Scholar · View at Scopus
  124. R. E. Blair, L. S. Deshpande, S. Sombati, M. R. Elphick, B. R. Martin, and R. J. DeLorenzo, “Prolonged exposure to WIN55,212-2 causes downregulation of the CB1 receptor and the development of tolerance to its anticonvulsant effects in the hippocampal neuronal culture model of acquired epilepsy,” Neuropharmacology, vol. 57, no. 3, pp. 208–218, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  125. A. C. Howlett, “Pharmacology of cannabinoid receptors,” Annual Review of Pharmacology and Toxicology, vol. 35, pp. 607–634, 1995. View at Google Scholar
  126. A. V. Goonawardena, G. Riedel, and R. E. Hampson, “Cannabinoids alter spontaneous firing, bursting, and cell synchrony of hippocampal principal cells,” Hippocampus, vol. 21, no. 5, pp. 520–531, 2011. View at Publisher · View at Google Scholar · View at PubMed
  127. P. K. Chanda, Y. Gao, L. Mark et al., “Monoacylglycerol lipase activity is a critical modulator of the tone and integrity of the endocannabinoid system,” Molecular Pharmacology, vol. 78, no. 6, pp. 996–1003, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  128. K. Hayakawa, K. Mishima, M. Hazekawa et al., “Cannabidiol potentiates pharmacological effects of Δ9-tetrahydrocannabinol via CB1 receptor-dependent mechanism,” Brain Research, vol. 1188, no. 1, pp. 157–164, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  129. J. E. Schlosburg, J. L. Blankman, J. Z. Long et al., “Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system,” Nature Neuroscience, vol. 13, no. 9, pp. 1113–1119, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  130. R. E. Hampson and S. A. Deadwyler, “Cannabinoids reveal the necessity of hippocampal neural encoding for short-term memory in rats,” Journal of Neuroscience, vol. 20, no. 23, pp. 8932–8942, 2000. View at Google Scholar · View at Scopus
  131. L. Robinson, S. McKillop-Smith, N. L. Ross et al., “Hippocampal endocannabinoids inhibit spatial learning and limit spatial memory in rats,” Psychopharmacology, vol. 198, no. 4, pp. 551–563, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  132. R. G. Pertwee, “The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin,” British Journal of Pharmacology, vol. 153, no. 2, pp. 199–215, 2008. View at Google Scholar
  133. C. C. Toth, N. M. Jedrzejewski, C. L. Ellis, and W. H. Frey, “Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain,” Molecular Pain, vol. 6, p. 16, 2010. View at Google Scholar · View at Scopus
  134. K. Chopra, V. Tiwari, V. Arora, and A. Kuhad, “Sesamol suppresses neuro-inflammatory cascade in experimental model of diabetic neuropathy,” Journal of Pain, vol. 11, no. 10, pp. 950–957, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  135. A. Dogrul, H. Gul, O. Yesilyurt, U. H. Ulas, and O. Yildiz, “Systemic and spinal administration of etanercept, a tumor necrosis factor α inhibitor, blocks tactile allodynia in diabetic mice,” Acta Diabetologica, pp. 1–8, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  136. S. Talbot, E. Chahmi, J. P. Dias, and R. Couture, “Key role for spinal dorsal horn microglial kinin B1 receptor in early diabetic pain neuropathy,” Journal of Neuroinflammation, vol. 7, no. 1, article 36, 2010. View at Publisher · View at Google Scholar · View at PubMed
  137. S. J. Carlisle, F. Marciano-Cabral, A. Staab, C. Ludwick, and G. A. Cabral, “Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation,” International Immunopharmacology, vol. 2, no. 1, pp. 69–82, 2002. View at Publisher · View at Google Scholar · View at Scopus
  138. J. Zhang, C. Hoffert, H. K. Vu, T. Groblewski, S. Ahmad, and D. O'Donnell, “Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models,” European Journal of Neuroscience, vol. 17, no. 12, pp. 2750–2754, 2003. View at Publisher · View at Google Scholar · View at Scopus
  139. G. Wotherspoon, A. Fox, P. McIntyre, S. Colley, S. Bevan, and J. Winter, “Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons,” Neuroscience, vol. 135, no. 1, pp. 235–245, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  140. Q. R. Liu, C. H. Pan, A. Hishimoto et al., “Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands,” Genes, Brain and Behavior, vol. 8, no. 5, pp. 519–530, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  141. J. L. Blankman, G. M. Simon, and B. F. Cravatt, “A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol,” Chemistry and Biology, vol. 14, no. 12, pp. 1347–1356, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  142. A. I. Gulyas, B. F. Cravatt, M. H. Bracey et al., “Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala,” European Journal of Neuroscience, vol. 20, no. 2, pp. 441–458, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  143. M. K. McKinney and B. E. Cravatt, “Structure and function of fatty acid amide hydrolase,” Annual Review of Biochemistry, vol. 74, pp. 411–432, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  144. T. P. Dinh, T. F. Freund, and D. Piomelli, “A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation,” Chemistry and Physics of Lipids, vol. 121, no. 1-2, pp. 149–158, 2002. View at Publisher · View at Google Scholar · View at Scopus
  145. A. Witting, L. Walter, J. Wacker, T. Moller, and N. Stella, “P2X7 receptors control 2-arachidonoylglycerol production by microglial cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 9, pp. 3214–3219, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  146. G. G. Muccioli, C. Xu, E. Odah et al., “Identification of a novel endocannabinoid-hydrolyzing enzyme expressed by microglial cells,” Journal of Neuroscience, vol. 27, no. 11, pp. 2883–2889, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  147. I. J. Lever, M. Robinson, M. Cibelli et al., “Localization of the endocannabinoid-degrading enzyme fatty acid amide hydrolase in rat dorsal root ganglion cells and its regulation after peripheral nerve injury,” Journal of Neuroscience, vol. 29, no. 12, pp. 3766–3780, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  148. G. Horvath, G. Kekesi, E. Nagy, and G. Benedek, “The role of TRPV1 receptors in the antinociceptive effect of anandamide at spinal level,” Pain, vol. 134, no. 3, pp. 277–284, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  149. J. Guindon, J. Desroches, and P. Beaulieu, “The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors,” British Journal of Pharmacology, vol. 150, no. 6, pp. 693–701, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  150. J. Guindon, A. Guijarro, D. Piomelli, and A. G. Hohmann, “Peripheral antinociceptive effects of inhibitors of monoacylglycerol lipase in a rat model of inflammatory pain,” British Journal of Pharmacology, vol. 163, no. 7, pp. 1464–1478, 2011. View at Publisher · View at Google Scholar · View at PubMed
  151. C. Potenzieri, T. S. Brink, and D. A. Simone, “Excitation of cutaneous C nociceptors by intraplantar administration of anandamide,” Brain Research, vol. 1268, pp. 38–47, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  152. S. G. Kinsey, J. Z. Long, S. T. O'Neal et al., “Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain,” Journal of Pharmacology and Experimental Therapeutics, vol. 330, no. 3, pp. 902–910, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  153. J. Z. Long, D. K. Nomura, R. E. Vann et al., “Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 48, pp. 20270–20275, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  154. D. R. Sagar, A. G. Gaw, B. N. Okine et al., “Dynamic regulation of the endocannabinoid system: implications for analgesia,” Molecular pain, vol. 5, p. 59, 2009. View at Google Scholar · View at Scopus
  155. D. Piomelli, “The molecular logic of endocannabinoid signalling,” Nature Reviews Neuroscience, vol. 4, no. 11, pp. 873–884, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  156. M. Beltramo, “Cannabinoid type 2 receptor as a target for chronic—pain,” Mini-Reviews in Medicinal Chemistry, vol. 9, no. 1, pp. 11–25, 2009. View at Publisher · View at Google Scholar · View at Scopus
  157. G. A. Thakur, R. Tichkule, S. Bajaj, and A. Makriyannis, “Latest advances in cannabinoid receptor agonists,” Expert Opinion on Therapeutic Patents, vol. 19, no. 12, pp. 1647–1673, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  158. S. M. Huang, T. Bisogno, T. J. Petros et al., “Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain,” Journal of Biological Chemistry, vol. 276, no. 46, pp. 42639–42644, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  159. V. M. Showalter, D. R. Compton, B. R. Martin, and M. E. Abood, “Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands,” Journal of Pharmacology and Experimental Therapeutics, vol. 278, no. 3, pp. 989–999, 1996. View at Google Scholar · View at Scopus
  160. S. M. Keyse, “Dual-specificity MAP kinase phosphatases (MKPs) and cancer,” Cancer and Metastasis Reviews, vol. 27, no. 2, pp. 253–261, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  161. S. Mukherjee, M. Adams, K. Whiteaker et al., “Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors,” European Journal of Pharmacology, vol. 505, no. 1–3, pp. 1–9, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  162. B. B. Yao, S. Mukherjee, Y. Fan et al., “In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor?” British Journal of Pharmacology, vol. 149, no. 2, pp. 145–154, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  163. A. N. Lozano-Ondoua, C. Wright, A. Vardanyan et al., “A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss,” Life Sciences, vol. 86, no. 17-18, pp. 646–653, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  164. V. Curto-Reyes, S. Llames, A. Hidalgo, L. Menendez, and A. Baamonde, “Spinal and peripheral analgesic effects of the CB2 cannabinoid receptor agonist AM1241 in two models of bone cancer-induced pain,” British Journal of Pharmacology, vol. 160, no. 3, pp. 561–573, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  165. M. M. Ibrahim, F. Porreca, J. Lai et al., “CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 8, pp. 3093–3098, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  166. E. J. Rahn, A. M. Zvonok, A. Makriyannis, and A. G. Hohmann, “Antinociceptive effects of racemic AM1241 and its chirally synthesized enantiomers: lack of dependence upon opioid receptor activation,” AAPS Journal, vol. 12, no. 2, pp. 147–157, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  167. G. C. Hsieh, M. Pai, P. Chandran et al., “Central and peripheral sites of action for CB2 receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats,” British Journal of Pharmacology, vol. 162, no. 2, pp. 428–440, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  168. J. L. Wilkerson et al., Cannabinoid 2 Receptor (CB2R) Selective Agonists Given Intrathecally Reverse Chronic Constriction Injury (CCI)-Induced Allodynia in Society for Neuroscience, Chicago, Ill, USA, 2009.
  169. J. L. Wilkerson et al., Selective Cannabinoid Receptor 2 (CB2) Agonists Administered Intrathecally Act as Indirect Agonists to Differentially Alter p38 MAPK Production in the Spinal Cord and Dorsal Root Ganglion in Neuropathic Rats in Society of Neuroscience, San Diego, Calif, USA, 2010.
  170. A. Leichsenring, M. Andriske, I. Backer, C. C. Stichel, and H. Lubbert, “Analgesic and antiinflammatory effects of cannabinoid receptor agonists in a rat model of neuropathic pain,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 379, no. 6, pp. 627–636, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  171. K. J. Valenzano, L. Tafesse, G. Lee et al., “Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy,” Neuropharmacology, vol. 48, no. 5, pp. 658–672, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  172. B. Hu, H. Doods, R. D. Treede, and A. Ceci, “Depression-like behaviour in rats with mononeuropathy is reduced by the CB2-selective agonist GW405833,” Pain, vol. 143, no. 3, pp. 206–212, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  173. N. Schuelert, C. Zhang, A. J. Mogg et al., “Paradoxical effects of the cannabinoid CB2 receptor agonist GW405833 on rat osteoarthritic knee joint pain,” Osteoarthritis and Cartilage, vol. 18, no. 11, pp. 1536–1543, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  174. K. Alawi and J. Keeble, “The paradoxical role of the transient receptor potential vanilloid 1 receptor in inflammation,” Pharmacology and Therapeutics, vol. 125, no. 2, pp. 181–195, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  175. T. Hagenacker, D. Ledwig, and D. Busselberg, “Feedback mechanisms in the regulation of intracellular calcium ([Ca2+]i) in the peripheral nociceptive system: role of TRPV-1 and pain related receptors,” Cell Calcium, vol. 43, no. 3, pp. 215–227, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  176. A. D. Khanolkar, D. Lu, M. Ibrahim et al., “Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity,” Journal of Medicinal Chemistry, vol. 50, no. 26, pp. 6493–6500, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  177. E. J. Rahn, G. A. Thakur, J. A. Wood, A. M. Zvonok, A. Makriyannis, and A. G. Hohmann, “Pharmacological characterization of AM1710, a putative cannabinoid CB 2 agonist from the cannabilactone class: antinociception without central nervous system side-effects,” Pharmacology Biochemistry and Behavior, vol. 98, no. 4, pp. 493–502, 2011. View at Publisher · View at Google Scholar · View at PubMed
  178. E. J. Rahn, A. M. Zvonok, G. A. Thakur, A. D. Khanolkar, A. Makriyannis, and A. G. Hohmann, “Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 327, no. 2, pp. 584–591, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  179. E. J. Rahn, G. A. Thakur, V. k. Vemuri et al., Prophylactic Treatment with Cannabinoids Suppresses the Development of Neuropathic Nociception Resulting from Treatment with the Chemotherapeutic Agent Paclitaxel in Rats in Society for Neuroscience, San Diego, Calif, USA, 2010.
  180. L. Luongo, E. Palazzo, S. Tambaro et al., “1-(2',4'-dichlorophenyl)-6-methyl-N-cyclohexylamine-1,4-dihy droindeno[1,2-c]pyrazole-3-carboxamide, a novel CB2 agonist, alleviates neuropathic pain through functional microglial changes in mice,” Neurobiology of Disease, vol. 37, no. 1, pp. 177–185, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  181. J. J. Xu, P. Diaz, F. Astruc-Diaz, S. Craig, E. Munoz, and M. Naguib, “Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain,” Anesthesia and Analgesia, vol. 111, no. 1, pp. 99–109, 2010. View at Publisher · View at Google Scholar · View at PubMed
  182. J. M. Frost, M. J. Dart, K. R. Tietje et al., “Indol-3-yl-tetramethylcyclopropyl ketones: effects of indole ring substitution on CB2 cannabinoid receptor activity,” Journal of Medicinal Chemistry, vol. 51, no. 6, pp. 1904–1912, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  183. B. B. Yao, G. Hsieh, A. V. Daza et al., “Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]- Amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging,” Journal of Pharmacology and Experimental Therapeutics, vol. 328, no. 1, pp. 141–151, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  184. B. B. Yao, G. C. Hsieh, J. M. Frost et al., “In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models,” British Journal of Pharmacology, vol. 153, no. 2, pp. 390–401, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  185. S. G. Kinsey, A. Mahadevan, B. Zhao et al., “The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects,” Neuropharmacology, vol. 60, no. 2-3, pp. 244–251, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  186. H. Ohta, T. Ishizaka, M. Tatsuzuki et al., “Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action,” Bioorganic and Medicinal Chemistry, vol. 16, no. 3, pp. 1111–1124, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  187. A. Gardin, K. Kucher, B. Kiese, and S. Appel-Dingemanse, “Cannabinoid receptor agonist 13, a novel cannabinoid agonist: first in human pharmacokinetics and safety,” Drug Metabolism and Disposition, vol. 37, no. 4, pp. 827–833, 2009. View at Publisher · View at Google Scholar · View at PubMed
  188. R. D. Hosking and J. P. Zajicek, “Therapeutic potential of cannabis in pain medicine,” British Journal of Anaesthesia, vol. 101, no. 1, pp. 59–68, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  189. A. F. Bar-Joseph, G. Richstein, A. Dar et al., “PRS-211,375, a novel selective CB2 receptor agonist, demonstrates analgesic activity in several animal models. Program No. 909.05,” in Proceedings of the Neuroscience Meeting Planner, Society for Neuroscience, New Orleans, La, USA, 2003.
  190. A. M. Bar-Joseph, S. Eliav, E. Weksler et al., “PRS-211,375, a novel CB2 selective cannabinoid receptor agonist demonstrates analgesic activity in two neuropathic pain models. Program No. 225.12,” in Proceedings of the Neuroscience Meeting Planner, Society for Neuroscience, San Diego, Calif, USA, 2004.
  191. G. M. Giblin, C. T. O'Shaughnessy, A. Naylor et al., “Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl) methyl]-4-(trifluoromethyl)-5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain,” Journal of Medicinal Chemistry, vol. 50, no. 11, pp. 2597–2600, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  192. A. Hervera, R. Negrete, S. Leánez et al., “The role of nitric oxide in the local antiallodynic and antihyperalgesic effects and expression of delta-opioid and cannabinoid-2 receptors during neuropathic pain in mice,” Journal of Pharmacology and Experimental Therapeutics, vol. 334, no. 3, pp. 887–896, 2010. View at Google Scholar